David H Gultekin

Prof. David H Gultekin

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALA. Craig Lockhart
A. Craig Lockhart
MRMace L. Rothenberg
Mace L. Rothenberg
JDJakob Dupont
Jakob Dupont
WCWendy Cooper
Wendy Cooper
PCPaul Chevalier
Paul Chevalier
WTWilliam P. Tew
William P. Tew
Purpose: Vascular endothelial growth factor (VEGF) Trap (aflibercept) is an angiogenesis inhibitor comprising portions of the extracellular domains of human VEGF receptors 1 and 2 fused to the Fc portion of human immunoglobulin G. This phase I study was designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of VEGF Trap administered intravenously (IV) every 2 weeks.Patients and Methods: Patients with refractory solid tumors or non-Hodgkin's lymphoma with adequate organ function were eligible. Pharmacokinetic/pharmacodynamic markers included measurement of plasma VEGF bound to VEGF Trap and free VEGF Trap. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was incorporated to measure the biologic effects of the drug on tumor vascularity and permeability.Results: The study enrolled 47 patients at doses ranging from 0.3 to 7.0 mg/kg IV every 2 weeks. Dose-limiting toxicities were rectal ulceration and proteinuria at the 7.0 mg/kg dose. Other mechanism-specific toxicities included hypertension. On the basis of these observations and on pharmacokinetics, the recommended phase II dose of VEGF Trap as a single agent is 4 mg/kg every 2 weeks. Three RECIST (Response Evaluation Criteria in Solid Tumors) –defined partial responses were observed, one at the 3.0 mg/kg and two at the 7.0 mg/kg dose level. Maximum plasma concentration of free VEGF Trap increased proportionally with dose. Maximal VEGF-bound VEGF Trap complex levels were reached at doses ≥ 2.0 mg/kg. Changes in volume transfer constant measured by DCE-MRI at baseline and at 24 hours after administration indicate a possible dose-related change in this pharmacodynamic marker.Conclusion: IV VEGF Trap was well tolerated at the dose levels tested. Pharmacodynamic and pharmacokinetic markers were indicative of VEGF blockade.

2 June 2009 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
WJWilliam R. R Jarnagin
William R. R Jarnagin
LSL. H. Schwartz
L. H. Schwartz
DGDavid H Gultekin
David H Gultekin
MGM. Gönen
M. Gönen
DHD. Haviland
D. Haviland
NKN. Kemeny
N. Kemeny
Background: This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome. Patients and methods: Thirty-four unresectable patients (26 ICC and eight HCC) were treated with HAI FUDR/dex. Radiologic dynamic and pharmacokinetic parameters related to tumor perfusion were analyzed and correlated with response and survival. Results: Partial responses were seen in 16 patients (47.1%); time to progression and response duration were 7.4 and 11.9 months, respectively. Median follow-up and median survival were 35 and 29.5 months, respectively; 2-year survival was 67%. DCE-MRI data showed that patients with pretreatment integrated area under the concentration curve of gadolinium contrast over 180 s (AUC 180) >34.2 mM·s had a longer median survival than those with AUC 180 <34 mM·s (35.1 versus 19.1 months, P = 0.002). Decreased volume transfer exchange between the vascular space and extracellular extravascular space (−ΔKtrans) and the corresponding rate constant (−Δkep) on the first post-treatment scan both predicted survival. Conclusions: In patients with unresectable primary liver cancer, HAI therapy can be effective and safe. Pretreatment and early post-treatment changes in tumor perfusion characteristics may predict treatment outcome.

20 November 2011 in European Radiology
Verified
Journal Article
Closed access
PDF file
MGM. J. Gollub
M. J. Gollub
DGDavid H Gultekin
David H Gultekin
OAO. Akin
O. Akin
RDR. K. Do
R. K. Do
JFJ. L. Fuqua
J. L. Fuqua
LSL. H. Schwartz
L. H. Schwartz

1 August 2013 in Radiology
Verified
Journal Article
Closed access
ODOlivio F. Donati
Olivio F. Donati
SJSung Il Jung
Sung Il Jung
HVHebert Alberto Vargas
Hebert Alberto Vargas
DGDavid H Gultekin
David H Gultekin
JZJunting Zheng
Junting Zheng
OAOguz Akin
Oguz Akin
We found that the best overall diagnostic accuracy and the highest interreader agreement for the detection of recurrent prostate cancer after radiation therapy were achieved with a combination of T... PurposeTo compare diagnostic accuracy of T2-weighted magnetic resonance (MR) imaging with that of multiparametric (MP) MR imaging combining T2-weighted imaging with diffusion-weighted (DW) MR imagi...

14 June 2011 in Oncology
Verified
Journal Article
Open access
PDF file
NKNancy E. Kemeny
Nancy E. Kemeny
LSLawrence Schwartz
Lawrence Schwartz
MGMithat Gönen
Mithat Gönen
AYAdam Yopp
Adam Yopp
DGDavid H Gultekin
David H Gultekin
WJWilliam R. R Jarnagin
William R. R Jarnagin
Objectives: This study investigated the efficacy and safety of adding systemic (IV) bevacizumab (Bev) to hepatic arterial infusion (HAI) with floxuridine (FUDR)/dexamethasone (Dex) in unresectable primary liver cancer. Methods: Patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) were treated with HAI FUDR/Dex plus IV Bev. Results were compared to a recent study of HAI without Bev in a similar patient population. Results: Twenty-two patients (18 ICC, 4 HCC) were treated with HAI FUDR/Dex plus Bev; 7 (31.8%) had partial response and 15 (68.2%) had stable disease. Median survival was 31.1 months (CI 14.14–33.59), progression-free survival (PFS) 8.45 months (CI 5.53–11.05), and hepatic PFS 11.3 months (CI 7.93–15.69). In the previous trial with HAI alone (no Bev), the response was 50%; median survival, PFS, and hepatic PFS were 29.5, 7.3, and 10.1 months. In the present trial, bilirubin elevation (>2 mg/dl) was seen in 24% of patients and biliary stents were placed in 13.6%, versus 5.8 and 0%, respectively, in the HAI trial without Bev. Due to increased biliary toxicity, the trial was prematurely terminated. Conclusion: Adding Bev to HAI FUDR/Dex appeared to increase biliary toxicity without clear improvement in outcome (median PFS 8.45 vs. 7.3 months, and median survival 31.1 vs. 29.5 months, for HAI + Bev vs. HAI alone groups, respectively).

1 May 2011 in European Radiology
Verified
Journal Article
Closed access
PDF file
OAOguz Akin
Oguz Akin
DGDavid H Gultekin
David H Gultekin
HVHebert Alberto Vargas
Hebert Alberto Vargas
JZJunting Zheng
Junting Zheng
CMChaya Moskowitz
Chaya Moskowitz
MZMichael J. Zelefsky
Michael J. Zelefsky